Почетна › Akutna bifentipska leukemija › Њујорк
Kliničke studije za Akutna bifentipska leukemija u državi Њујорк
11 studija za Akutna bifentipska leukemija traži učesnike na lokacijama u državi Њујорк.
Gradovi u državi Њујорк
- New York City10 студија
- Greenburgh5 студија
- Queens4 студија
- The Bronx3 студија
- Syracuse3 студија
- Albany3 студија
Zvanični tekst studije (na engleskom)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Albany Medical Center, Albany
- Roswell Park Cancer Institute, Buffalo
- The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park
- и још 7
Тражи се учесникФаза 2
365 Days · Оба пола · Ажурирано 27. 10. 2026. · NCT06317662Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- New York Medical College, Valhalla
Тражи се учесникФаза 1/2
Узраст од 13 до 90 · Оба пола · Ажурирано 26. 10. 2026. · NCT06533579Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Memorial Sloan- Kettering Cancer Center, New York
Тражи се учесникФаза 1
Узраст од 1 до 30 · Оба пола · Ажурирано 22. 10. 2026. · NCT06177067A Study of Revumenib and Mezigdomide in People With Leukemia
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- и још 1
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 20. 10. 2026. · NCT07356154A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Montefiore Medical Center, New York
Тражи се учесникФаза 1/2
30 Days · Оба пола · Ажурирано 9. 10. 2026. · NCT04065399A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Memorial Sloan Kettering Cancer Center, New York
Тражи се учесникФаза 1
Узраст од 12 до 78 · Оба пола · Ажурирано 29. 9. 2026. · NCT03802695Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Albany Medical Center, Albany
- Maimonides Medical Center, Brooklyn
- Roswell Park Cancer Institute, Buffalo
- и још 12
Тражи се учесникФаза 3
365 Days – 25 Years · Оба пола · Ажурирано 25. 8. 2026. · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Albany Medical Center, Albany
- Maimonides Medical Center, Brooklyn
- NYU Langone Hospital - Long Island, Mineola
- и још 7
Тражи се учесникФаза 1/2
До 22 година · Оба пола · Ажурирано 25. 8. 2026. · NCT04726241Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 7. 7. 2026. · NCT07216443Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
- Memorial Sloan Kettering Cancer Center, New York
Тражи се учесникФаза 1
Узраст 12 и старији · Оба пола · Ажурирано 8. 1. 2026. · NCT04872478Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital New York-Presbyterian, New York
- Memorial Sloan Kettering Cancer Center, New York
Тражи се учесникФаза 1
Узраст од 1 до 21 · Оба пола · Ажурирано 6. 12. 2024. · NCT05476770Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.